Board committees’ current and future focus

Board Committee Focus 2021/2022 and Outlook for the Year Ahead

Board committees’ current and future focus

Board Committee Focus 2021/2022 and Outlook for the Year Ahead

Giving effect to corporate governance/alignment to King IV principles

COMMITTEES OF THE BOARD | PRINCIPLE 8 applied

The Board ensures that its arrangements for delegation within its own structures promote independent judgement and assists with the balance of power and the effective discharge of duties.

Giving effect to corporate governance / alignment to King IV principles

COMMITTEES OF THE BOARD | PRINCIPLE 8 applied

The Board ensures that its arrangements for delegation within its own structures promote independent judgement and assists with the balance of power and the effective discharge of duties.

Governance, Social and Ethics Committee

Members of the Committee over the period 1 April 2021 to 31 March 2022

  • G Leong (Chair) (from 2 December 2021)
  • S Fakie (Chair) (stood down from 2 December 2021)
  • A Ramalho
  • Dr M Vaithilingum (stood down from 2 December 2021)
  • T Mokgatlha (from 2 December 2021)
  • P Mthethwa
  • B Damons (outside co-opted member)
  • R Reddy

Gary Leong CHAIRPERSON

Role

The overarching role of the Committee entails discharging its statutory duties by ensuring that the Company acts ethically and that there is an ethical culture with regards to:
    • Sustainable development
    • Corporate citizenship
    • Stakeholder relationships
  • With regards to employment equity as well as the safety and the dignity of employees, the Committee is entitled to rely on the work of the Human Resources and Remuneration Committee but should at least annually obtain assurances from the Human Resources and Remuneration Committee that this responsibility has been adequately addressed.
  • With regards to the safety of employees particularly in relation to the production of safe blood, the Committee is entitled to rely on the oversight of the Clinical Governance Committee (“CGC”) but should at least annually obtain assurances from the CGC that this responsibility has been adequately addressed

Declaration

The committee has executed its responsibilities in accordance with an approved mandate.

Risks

R-9.png
R-10
R-11

Capitals

man-capital-red
social-capital-red
natural-capital-red
int-capital-red

King IV™

k-1
k-2
k-3
k-16

Stakeholders

regulators-stake
employee-stakeholder-icon
donors

Governance, Social and Ethics Committee

Members of the Committee over the period 1 April 2021 to 31 March 2022

  • G Leong (Chair) (from 2 December 2021)
  • S Fakie (Chair) (stood down from 2 December 2021)
  • A Ramalho
  • Dr M Vaithilingum (stood down from 2 December 2021)
  • T Mokgatlha (from 2 December 2021)
  • P Mthethwa
  • B Damons (outside co-opted member)
  • R Reddy

Gary Leong CHAIRPERSON

Role

The overarching role of the Committee entails discharging its statutory duties by ensuring that the Company acts ethically and that there is an ethical culture with regards to:
    • Sustainable development
    • Corporate citizenship
    • Stakeholder relationships
  • With regards to employment equity as well as the safety and the dignity of employees, the Committee is entitled to rely on the work of the Human Resources and Remuneration Committee but should at least annually obtain assurances from the Human Resources and Remuneration Committee that this responsibility has been adequately addressed.
  • With regards to the safety of employees particularly in relation to the production of safe blood, the Committee is entitled to rely on the oversight of the Clinical Governance Committee (“CGC”) but should at least annually obtain assurances from the CGC that this responsibility has been adequately addressed

Declaration

The committee has executed its responsibilities in accordance with an approved mandate.

Risks

R-9.png
R-10
R-11

Capitals

man-capital-red
social-capital-red
natural-capital-red
int-capital-red

King IV™

k-1
k-2
k-3
k-16

Stakeholders

regulators-stake
employee-stakeholder-icon
donors

Nomination Committee

Members of the Committee over the period 1 April 2021 to 31 March 2022

  • T Mokgatlha (Chair) (from 2 December 2021)
  • A Ramalho (Chair until 2 December 2021)
  • Dr J Black (joined 2 December 2021)
  • Dr P Knox (until 20 November 2021)
  • P Mthethwa
  • Rob Theunissen (until 20 November 2021)
  • Dr M Vaithilingum (joined 2 December 2021)

T. Mokgatlha cHAIRPERSON

Role

The overarching role of the Committee entails assisting the Board in ensuring that:

  • The Board and its Committees are appropriately constituted with the right skills, qualification and training
  • Qualified directors are identified for nomination, election and appointment to the Board through a formal and transparent process
  • There is an established and maintained Board continuity programme

Declaration

The committee has executed its responsibilities in accordance with an approved mandate.

Risks

Capitals

human-capital-red
int-capital-red
social-capital-red

King IV™

Stakeholders

Nomination Committee

Members of the Committee over the period 1 April 2021 to 31 March 2022

  • T Mokgatlha (Chair) (from 2 December 2021)
  • A Ramalho (Chair until 2 December 2021)
  • Dr J Black (joined 2 December 2021)
  • Dr P Knox (until 20 November 2021)
  • P Mthethwa
  • Rob Theunissen (until 20 November 2021)
  • Dr M Vaithilingum (joined 2 December 2021)

T. Mokgatlha cHAIRPERSON

Role

The overarching role of the Committee entails assisting the Board in ensuring that:

  • The Board and its Committees are appropriately constituted with the right skills, qualification and training
  • Qualified directors are identified for nomination, election and appointment to the Board through a formal and transparent process
  • There is an established and maintained Board continuity programme

Declaration

The committee has executed its responsibilities in accordance with an approved mandate.

Risks

Capitals

human-capital-red
int-capital-red
social-capital-red

King IV™

Stakeholders

Risk, Technology and Information Governance Committee

Members of the Committee over the period 1 April 2021 to 31 March 2022

Members
  • F Burn
  • A Ramalho (from 2 December 2021)
  • C Henry (appointed 20 November 2021)
  • G Leong

Executives
  • R Reddy
  • K van den Berg

Faith Burn cHAIRPERSON

Role

The overarching role of the Committee entails assisting the Board in overseeing that the following areas support the Company in setting and achieving its strategic objectives:
  • The governance of risk management, including the system of compliance risk governance
  • Technology and Information governance

Declaration

The committee has executed its responsibilities in accordance with a defined mandate.

Risks

R-1
R-2
R-3
R-4
R-5
R-6-1.png
R-7.png
R-8
R-9.png
R-10.png

Capitals

man-capital-red
int-capital-red
finance-capital-red

King IV™

k-11
k-12
k-13

Stakeholders

suppliers
medical-stake
donors
blood-partners

Risk, Technology and Information Governance Committee

Members of the Committee over the period 1 April 2021 to 31 March 2022

Members
  • F Burn
  • A Ramalho (from 2 December 2021)
  • C Henry (appointed 20 November 2021)
  • G Leong

Executives
  • R Reddy
  • K van den Berg

Faith Burn cHAIRPERSON

Role

The overarching role of the Committee entails assisting the Board in overseeing that the following areas support the Company in setting and achieving its strategic objectives:
  • The governance of risk management, including the system of compliance risk governance
  • Technology and Information governance

Declaration

The committee has executed its responsibilities in accordance with a defined mandate.

Risks

R-1
R-2
R-3
R-4
R-5
R-6-1.png
R-7.png
R-8
R-9.png
R-10.png

Capitals

man-capital-red
int-capital-red
finance-capital-red

King IV™

k-11
k-12
k-13

Stakeholders

suppliers
medical-stake
donors
blood-partners
EVALUATION AND PERFORMANCE OF THE BOARD
EVALUATION AND PERFORMANCE OF THE BOARD

How can we help you?

Let's Connect

Head Office

  • 1 Constantia Boulevard Constantia Kloof, Roodepoort, 1709
  • (011) 761-9000
  • customerservice@sanbs.org.za

Main Links

Ⓒ 2022 - All Rights Are Reserved. SANBS Integrated Report. Created by Joshero (Pty) Ltd.

Head Office

  • 1 Constantia Boulevard Constantia Kloof, Roodepoort, 1709
  • (011) 761-9000
  • customerservice@sanbs.org.za

Main Links

Ⓒ 2022 - All Rights Are Reserved. SANBS Integrated Report. Created by Joshero (Pty) Ltd.